Saad  Usmani  to  Chronic Disease
                            
                            
                                This is a "connection" page, showing publications  Saad  Usmani  has written about  Chronic Disease.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.134
         
        
        
     
 
    
        
        - 
            Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 07 18; 396(10245):186-197.
            
            
                Score: 0.134